HI
ENTA icon

Harbour Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Harbour Investments’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed – – 2933
2021
Q3 		$0 Hold
3
– – ﹤0.01% 3799
2021
Q2 		$0 Hold
3
– – ﹤0.01% 3820
2021
Q1 		$0 Buy
+3
New +$150 ﹤0.01% 3628

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Harbour Investments's ENTA Position: Q4 2021 in Review

Harbour Investments sold out of Enanta Pharmaceuticals (ENTA) in Q4 2021, closing a stake of 3 shares.

Harbour Investments first reported a position in ENTA in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 179 funds tracked by Wall St. Rank hold ENTA as of Q4 2021.

  • Harbour Investments reported no remaining Enanta Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 3 Enanta Pharmaceuticals shares in Q4 2021.
  • Harbour Investments first reported a position in Enanta Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Enanta Pharmaceuticals position peaked at $0 in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.